01-01-2017
Results of a Randomized Open Multicenter Comparative Study of the Tolerability and Safety of Gilenya (fingolimod) in Patients with Remitting Multiple Sclerosis (the GIMN study)
Published in: Neuroscience and Behavioral Physiology | Issue 1/2017
Login to get access